Johnson C - Search Results

1

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.

Evans R, Lee K, Wallace PK, Reid M, Muhitch J, Dozier A, Mesa C, Luaces PL, Santos-Morales O, Groman A, Cedeno C, Cinquino A, Fisher DT, Puzanov I, Opyrchal M, Fountzilas C, Dai T, Ernstoff M, Attwood K, Hutson A, Johnson C, Mazorra Z, Saavedra D, Leon K, Lage A, Crombet T, Dy GK. Evans R, et al. Among authors: johnson c. Front Oncol. 2022 Aug 3;12:958043. doi: 10.3389/fonc.2022.958043. eCollection 2022. Front Oncol. 2022. PMID: 35992783 Free PMC article.

2

A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.

Fountzilas C, Javle M, Tan W, Ma Y, Fetterly G, Iyer R, Johnson C. Fountzilas C, et al. Among authors: johnson c. Cancer. 2018 Oct 1;124(19):3890-3899. doi: 10.1002/cncr.31676. Epub 2018 Oct 9. Cancer. 2018. PMID: 30299542 Free PMC article. Clinical Trial.

3

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance.

Shaurova T, Dy GK, Battaglia S, Hutson A, Zhang L, Zhang Y, Lovly CM, Seshadri M, Goodrich DW, Johnson CS, Hershberger PA. Shaurova T, et al. Cancers (Basel). 2020 Mar 13;12(3):675. doi: 10.3390/cancers12030675. Cancers (Basel). 2020. PMID: 32183160 Free PMC article.

4

A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.

Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ, Schwartz J, Brattain MG, Hutson A, French R, Johnson CS. Fakih MG, et al. Clin Cancer Res. 2007 Feb 15;13(4):1216-23. doi: 10.1158/1078-0432.CCR-06-1165. Clin Cancer Res. 2007. PMID: 17317832 Clinical Trial.

5

Vitamin D₃ enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk.

Bunch BL, Ma Y, Attwood K, Amable L, Luo W, Morrison C, Guru KA, Woloszynska-Read A, Hershberger PA, Trump DL, Johnson CS. Bunch BL, et al. Among authors: johnson cs. Cancer Med. 2019 May;8(5):2449-2461. doi: 10.1002/cam4.2119. Epub 2019 Apr 10. Cancer Med. 2019. PMID: 30972950 Free PMC article.

6

A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.

Ramnath N, Daignault-Newton S, Dy GK, Muindi JR, Adjei A, Elingrod VL, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Troeschel S, Johnson CS, Trump DL. Ramnath N, et al. Among authors: johnson cs. Cancer Chemother Pharmacol. 2013 May;71(5):1173-82. doi: 10.1007/s00280-013-2109-x. Epub 2013 Feb 23. Cancer Chemother Pharmacol. 2013. PMID: 23435876 Free PMC article. Clinical Trial.

7

Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model.

Mazzilli SA, Hershberger PA, Reid ME, Bogner PN, Atwood K, Trump DL, Johnson CS. Mazzilli SA, et al. Cancer Prev Res (Phila). 2015 Oct;8(10):895-904. doi: 10.1158/1940-6207.CAPR-14-0403. Epub 2015 Aug 14. Cancer Prev Res (Phila). 2015. PMID: 26276745 Free PMC article.

8

Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue.

Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME. Menezes RJ, et al. Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1104-10. doi: 10.1158/1055-9965.EPI-07-2713. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18483332 Free PMC article.

9

Serum vitamin D metabolites in colorectal cancer patients receiving cholecalciferol supplementation: correlation with polymorphisms in the vitamin D genes.

Muindi JR, Adjei AA, Wu ZR, Olson I, Huang H, Groman A, Tian L, Singh PK, Sucheston LE, Johnson CS, Trump DL, Fakih MG. Muindi JR, et al. Horm Cancer. 2013 Aug;4(4):242-50. doi: 10.1007/s12672-013-0139-9. Epub 2013 Feb 28. Horm Cancer. 2013. PMID: 23456391 Free PMC article.

10

TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).

Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, Bshara W, Pili R, Trump DL, Johnson C, Woloszynska A. Bunch B, et al. Among authors: johnson c. Cell Cycle. 2019 Sep;18(17):2055-2066. doi: 10.1080/15384101.2019.1638693. Epub 2019 Jul 18. Cell Cycle. 2019. PMID: 31318640 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12,092 results

Search Page